Allogene Therapeutics Stock Price, News & Analysis
ALLO
NASDAQ
Company Description
Welcome to the overview page for Allogene Therapeutics (ALLO), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
$1.39
+0.72%
+0.01
Last updated: December 28, 2025 at 16:18
-36.41 %
Performance 1 year
$314.6M
224.7M
Latest News
SEC Filings
Insider Radar
Net Sellers
90-Day Summary
0
Shares Bought
38,316
Shares Sold
3
Transactions
Most Recent Transaction
Beneski Benjamin Machinas
(SVP, Chief Technical Officer)
sold
786 shares
@ $1.22
on Nov 17, 2025
Based on SEC Form 4 filings over the last 90 days.
Financial Highlights
$22,000
Revenue (TTM)
-$257,590,000
Net Income (TTM)
-$1.32
-$200,300,000
Operating Cash Flow
-1,000,000.00%
-1,000,000.00%
Upcoming Events
JAN
01
January 1, 2026 - June 30, 2026
Clinical
ALPHA3 Phase 2 futility analysis
Alpha3 pivotal Phase 2 MRD conversion futility analysis expected H1 2026
JAN
01
January 1, 2026 - June 30, 2026
Clinical
ALLO-329 RESOLUTION PoC update
PoC and biomarker results update for ALLO-329 RESOLUTION trial in H1 2026
JAN
01
January 1, 2026 - June 30, 2026
Clinical
Futility analysis
Futility analysis for ALPHA3 trial in first-line large B-cell lymphoma
JAN
01
January 1, 2026
Clinical
Lymphodepletion futility analysis
JAN
01
January 1, 2026 - June 30, 2026
Clinical
Interim futility analysis
Pivotal Phase 2 ALPHA3 interim futility analysis for cema-cel in 1L LBCL (1H 2026)
JAN
01
January 1, 2026
Clinical
Interim EFS analysis
JAN
01
January 1, 2026 - June 30, 2026
Clinical
MRD conversion futility analysis
Interim futility analysis on MRD conversion in ALPHA3 Phase 2 trial
DEC
01
December 1, 2026
Clinical
Primary EFS data
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Allogene Therapeutics (ALLO)?
The current stock price of Allogene Therapeutics (ALLO) is $1.38 as of December 26, 2025.
What is the market cap of Allogene Therapeutics (ALLO)?
The market cap of Allogene Therapeutics (ALLO) is approximately 314.6M. Learn more about what market capitalization means .
What is the revenue (TTM) of Allogene Therapeutics (ALLO) stock?
The trailing twelve months (TTM) revenue of Allogene Therapeutics (ALLO) is $22,000.
What is the net income of Allogene Therapeutics (ALLO)?
The trailing twelve months (TTM) net income of Allogene Therapeutics (ALLO) is -$257,590,000.
What is the earnings per share (EPS) of Allogene Therapeutics (ALLO)?
The diluted earnings per share (EPS) of Allogene Therapeutics (ALLO) is -$1.32 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Allogene Therapeutics (ALLO)?
The operating cash flow of Allogene Therapeutics (ALLO) is -$200,300,000. Learn about cash flow.
What is the profit margin of Allogene Therapeutics (ALLO)?
The net profit margin of Allogene Therapeutics (ALLO) is -1,000,000.00%. Learn about profit margins.
What is the operating margin of Allogene Therapeutics (ALLO)?
The operating profit margin of Allogene Therapeutics (ALLO) is -1,000,000.00%. Learn about operating margins.
What is the current ratio of Allogene Therapeutics (ALLO)?
The current ratio of Allogene Therapeutics (ALLO) is 8.54, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of Allogene Therapeutics (ALLO)?
The operating income of Allogene Therapeutics (ALLO) is -$273,199,000. Learn about operating income.